Results 171 to 180 of about 25,486 (236)

Comparative Study of the Quality of Life of Patients With Ototoxicity Due to Platinum-Based Chemotherapy, With Hearing Aid Versus Those Without: Study Protocol for a Randomized Pilot Study-The PROTOTOX Study.

JMIR Res Protoc
Mastronicola R, Kayser E, Fernandez Y, Dolivet G.   +3 more
europepmc   +1 more source

Efficacy and safety of treatment regimens for drug-resistant tuberculosis in different regions: a systematic review and meta-analysis. [PDF]

BMC Infect Dis
Geng X, Zhang F, Liu R, Zhang F, Li Z, Li L.   +5 more
europepmc   +1 more source

New Insight into Potential Otoprotective Effects of Lactoferrin: Is It Paradoxically Ototoxic? An Experimental Investigation. [PDF]

Audiol Res
Mutlu A, Gunduz AY, Bakici B, Erinc M, Bulut E, Ersoy O, Celik S, Cakan D, Kalcioglu MT.   +8 more
europepmc   +1 more source

Plazomicin: A promising novel antimicrobial in the era of bacterial resistance (Review). [PDF]

Exp Ther Med
Abouelkheir M, Taha AE, Taher IA, Saad Eldien HM, Bakhaat GA.   +4 more
europepmc   +1 more source

Comparison of associations suggests mainly distinct pools of genetic risk factors contribute to cisplatin-induced hearing loss and hearing difficulty in the general population. [PDF]

Front Pharmacol
Shahbazi M, Wheeler HE, Zhang X, Frisina RD, Travis LB, Dolan ME.   +5 more
europepmc   +1 more source

Ototoxic impacts of adipose-derived extracts on a murine auditory cell line: molecular insights from proteomic analyses. [PDF]

Int J Obes (Lond)
Olou AA, Tom W, Krzyzanowski G, Jiang C, Chandel D, Fernando N, Thelagathoti R, Cosgrove D, Fernando MR.   +8 more
europepmc   +1 more source

Lower, more frequent cisplatin dosing minimizes hearing loss in head and neck cancer. [PDF]

JCI Insight
Fernandez KA, Chowdhury AS, Bonczkowski A, Allen PD, Campbell MH, Lee DS, Malhotra C, Page BR, Mulford DA, Ortiz CE, Santa Maria PL, Kullar P, Khan SA, Newlands SD, Schmitt NC, Cunningham LL.   +15 more
europepmc   +1 more source

A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation. [PDF]

Theranostics
Yin Z, Lu S, Wu L, Sun Y, Blake DC, Chen J, Landegger LD, Ho W, Xiu B, Jones AP, Muzikansky A, Shih HA, Stankovic KM, Plotkin SR, Xu L.   +14 more
europepmc   +1 more source

High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial. [PDF]

IJTLD Open
Snobre J, Gasana J, Decroo T, Mucyo Y, Jacobs BKM, Rigouts L, Martin IC, Herssens N, Hakizayezu F, Ntihumbya JB, Kilibazayire A, de Viron E, Runyambo D, Ndayishimiye C, Merle CS, Muvunyi CM, Migambi P, Sturkenboom MGG, de Jong BC, Ngabonziza JCS.   +19 more
europepmc   +1 more source